Accell siRNA achieves what no other RNAi product can claim: delivery into difficult-to-transfect cells without transfection reagents, virus, or instrumentation. Researchers around the world are achieving targeted gene silencing in neuronal, immune, and primary cells that had previously been beyond the reach of conventional RNAi products due to toxicity caused by transfection reagents or undesirable viral responses.